Skip to main content

Table 4 An independent set of 44 GBM specimens to examine the effects of nuclear FABP7 and EGFR expression on patient survival

From: Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma

Case #

Diagnosis

Age

Survival (wk)

Censor

FABP7 Nu

EGFR IHC

New Category*

17

GBM

54.2

73.2

1

0

0

0

30

GBM

24.3

203.9

1

0

0

0

45

GBM

45.2

67.9

1

0

0

0

46

GBM

26.9

146.7

0

0

0

0

66

GBM

17.5

133.5

0

0

0

0

68

GBM

31.6

146.9

1

0

0

0

81

GBM

51.1

60.6

1

0

0

0

84

GBM

43.6

66.8

0

0

0

0

87

GBM

59.9

43.4

1

0

0

0

91

GBM

46.4

383.0

0

0

0

0

94

GBM

54.0

33.7

1

0

0

0

98

GBM

39.1

48.6

1

0

1

1

99

GBM

56.9

128.1

1

0

1

1

107

GBM

59.1

79.8

1

0

2

1

110

GBM

45.2

35.1

1

0

2

1

148

GBM

59.8

35.1

1

0

2

1

194

GBM

54.8

32.7

1

0

2

1

225

GBM

54.1

94.3

1

0

2

1

243

GBM

50.6

76.8

1

0

2

1

263

GBM

54.7

123.1

1

0

2

1

277

GBM

42.5

25.1

0

0

2

1

284

GBM

47.7

92.3

1

0

2

1

29

GBM

35.3

97.0

1

0

2

1

89

GBM

55.2

45.1

1

1

0

2

273

GBM

42.5

39.0

0

1

0

2

4

GBM

51.0

29.5

1

1

0

2

21

GBM

59.3

32.7

1

1

0

2

32

GBM

58.2

22.1

1

1

0

2

53

GBM

51.2

23.8

1

2

0

2

54

GBM

33.1

32.7

0

2

0

2

58

GBM

37.2

31.1

1

2

0

2

61

GBM

12.8

12.3

0

2

0

2

88

GBM

52.2

93.9

1

2

0

2

100

GBM

45.8

11.3

1

2

0

2

103

GBM

55.1

13.9

1

2

2

3

105

GBM

41.7

46.1

1

2

2

3

106

GBM

43.8

10.5

0

2

2

3

207

GBM

51.3

27.1

1

2

2

3

240

GBM

45.2

13.3

1

2

2

3

247

GBM

58.7

43.3

1

2

2

3

265

GBM

58.8

80.1

1

2

2

3

34

GBM

54.4

36.0

1

1

1

3

38

GBM

23.0

24.1

1

1

2

3

50

GBM

25.0

41.0

1

1

2

3

  1. *Based on nuclear FABP7 and EGFR immunoreactivity: dual negative as "0", nuclear FABP7-/EGFR+ as "1", nuclear FABP7+/EGFR- as "2", and dual positive as "3"